96 related articles for article (PubMed ID: 26795472)
1. The Use of Withaferin A to Study Intermediate Filaments.
Mohan R; Bargagna-Mohan P
Methods Enzymol; 2016; 568():187-218. PubMed ID: 26795472
[TBL] [Abstract][Full Text] [Related]
2. Vimentin Phosphorylation Underlies Myofibroblast Sensitivity to Withaferin A In Vitro and during Corneal Fibrosis.
Bargagna-Mohan P; Lei L; Thompson A; Shaw C; Kasahara K; Inagaki M; Mohan R
PLoS One; 2015; 10(7):e0133399. PubMed ID: 26186445
[TBL] [Abstract][Full Text] [Related]
3. Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis.
Bargagna-Mohan P; Deokule SP; Thompson K; Wizeman J; Srinivasan C; Vooturi S; Kompella UB; Mohan R
PLoS One; 2013; 8(5):e63881. PubMed ID: 23667686
[TBL] [Abstract][Full Text] [Related]
4. Corneal antifibrotic switch identified in genetic and pharmacological deficiency of vimentin.
Bargagna-Mohan P; Paranthan RR; Hamza A; Zhan CG; Lee DM; Kim KB; Lau DL; Srinivasan C; Nakayama K; Nakayama KI; Herrmann H; Mohan R
J Biol Chem; 2012 Jan; 287(2):989-1006. PubMed ID: 22117063
[TBL] [Abstract][Full Text] [Related]
5. Withaferin a alters intermediate filament organization, cell shape and behavior.
Grin B; Mahammad S; Wedig T; Cleland MM; Tsai L; Herrmann H; Goldman RD
PLoS One; 2012; 7(6):e39065. PubMed ID: 22720028
[TBL] [Abstract][Full Text] [Related]
6. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin.
Bargagna-Mohan P; Hamza A; Kim YE; Khuan Abby Ho Y; Mor-Vaknin N; Wendschlag N; Liu J; Evans RM; Markovitz DM; Zhan CG; Kim KB; Mohan R
Chem Biol; 2007 Jun; 14(6):623-34. PubMed ID: 17584610
[TBL] [Abstract][Full Text] [Related]
7. Withaferin-A Can Be Used to Modulate the Keratin Network of Intermediate Filaments in Human Epidermal Keratinocytes.
Keeling MC; Gavara N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32585813
[TBL] [Abstract][Full Text] [Related]
8. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation.
Thaiparambil JT; Bender L; Ganesh T; Kline E; Patel P; Liu Y; Tighiouart M; Vertino PM; Harvey RD; Garcia A; Marcus AI
Int J Cancer; 2011 Dec; 129(11):2744-55. PubMed ID: 21538350
[TBL] [Abstract][Full Text] [Related]
9. Modulating endothelial barrier function by targeting vimentin phosphorylation.
Liu T; Ghamloush MM; Aldawood A; Warburton R; Toksoz D; Hill NS; Tang DD; Kayyali US
J Cell Physiol; 2014 Oct; 229(10):1484-93. PubMed ID: 24648251
[TBL] [Abstract][Full Text] [Related]
10. Barrier protective effects of withaferin A in HMGB1-induced inflammatory responses in both cellular and animal models.
Lee W; Kim TH; Ku SK; Min KJ; Lee HS; Kwon TK; Bae JS
Toxicol Appl Pharmacol; 2012 Jul; 262(1):91-8. PubMed ID: 22561332
[TBL] [Abstract][Full Text] [Related]
11. The steroidal lactone withaferin A impedes T-cell motility by inhibiting the kinase ZAP70 and subsequent kinome signaling.
Fazil MHUT; Chirumamilla CS; Perez-Novo C; Wong BHS; Kumar S; Sze SK; Vanden Berghe W; Verma NK
J Biol Chem; 2021 Dec; 297(6):101377. PubMed ID: 34742736
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic inhibition of reactive gliosis blocks TNF-α-mediated neuronal apoptosis.
Livne-Bar I; Lam S; Chan D; Guo X; Askar I; Nahirnyj A; Flanagan JG; Sivak JM
Cell Death Dis; 2016 Sep; 7(9):e2386. PubMed ID: 27685630
[TBL] [Abstract][Full Text] [Related]
13. Development of withaferin A analogs as probes of angiogenesis.
Yokota Y; Bargagna-Mohan P; Ravindranath PP; Kim KB; Mohan R
Bioorg Med Chem Lett; 2006 May; 16(10):2603-7. PubMed ID: 16513346
[TBL] [Abstract][Full Text] [Related]
14. Production of reactive oxygen species by withaferin A causes loss of type collagen expression and COX-2 expression through the PI3K/Akt, p38, and JNK pathways in rabbit articular chondrocytes.
Yu SM; Kim SJ
Exp Cell Res; 2013 Nov; 319(18):2822-34. PubMed ID: 24016823
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the contribution of actin and vimentin intermediate filaments to mechanical phenotype of suspended cells using high-throughput deformability measurements and computational modeling.
Gladilin E; Gonzalez P; Eils R
J Biomech; 2014 Aug; 47(11):2598-605. PubMed ID: 24952458
[TBL] [Abstract][Full Text] [Related]
16. Withaferin A is an inhibitor of endothelial protein C receptor shedding in vitro and in vivo.
Ku SK; Han MS; Bae JS
Food Chem Toxicol; 2014 Jun; 68():23-9. PubMed ID: 24632454
[TBL] [Abstract][Full Text] [Related]
17. The type III intermediate filament vimentin regulates organelle distribution and modulates autophagy.
Biskou O; Casanova V; Hooper KM; Kemp S; Wright GP; Satsangi J; Barlow PG; Stevens C
PLoS One; 2019; 14(1):e0209665. PubMed ID: 30699149
[TBL] [Abstract][Full Text] [Related]
18. Role of phosphorylation in keratin and vimentin filament integrity in cultured thyroid epithelial cells.
Deery WJ
Cell Motil Cytoskeleton; 1993; 26(4):325-39. PubMed ID: 7507800
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet, anticoagulant, and profibrinolytic activities of withaferin A.
Ku SK; Bae JS
Vascul Pharmacol; 2014 Mar; 60(3):120-6. PubMed ID: 24534482
[TBL] [Abstract][Full Text] [Related]
20. Withaferin A activates TRIM16 for its anti-cancer activity in melanoma.
Nagy Z; Cheung BB; Tsang W; Tan O; Herath M; Ciampa OC; Shadma F; Carter DR; Marshall GM
Sci Rep; 2020 Nov; 10(1):19724. PubMed ID: 33184347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
